This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary to get the Daily Monster Market Commentary and join the 2,950 subscribers getting it for FREE!
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Subscribe
Equity Markets are taking a wild ride today, with the S&P 500 down by nearly one percent at one point. But there has been a bit of snap back, with a recovery off the lows. Biotech just continues to get pounded, while Technology has had a rough go as well. Apple has managed to hold despite the weak day.
The SP 500 appears fine on the chart below with no significant technical damage. All the gaps have now been completely filled, while the index is finding support comfortable in its early October trading range. It is worth noting, a new downtrend line, drawn now in red. This is the first time that has been put in; the test will come around 2,560, which way the market will go.
Subscribe to the MCM Stock Market Commentary to get it Daily and join the 2,950 subscribers getting it for FREE!
The damage in Biotech is notable, and I have now drawn in a new dotted yellow support line around the $320 level in Nasdaq Biotech ETF ($IBB). It is a level we have not paid much attention to in the past, but we shall now.
Celgene reports results in the morning, and analysts are looking for revenue of $3.417 billion on EPS of $1.88. More critical will be the sale for Revlimid, it lead drug. Additionally, commentary around its pipeline or Ozanimod will be critical. It is hard to say the chart has found a bottom, but it seems a bit closer.
It took awhile, but the $XLK has now moved back into its trading channel, and that is good. Now some sideways consolidation would be nice. We can also see the gap has been filled from October 19.
Apple continues to hang tight, and while it hasn’t reversed course, it has broken down either. Apple is still the key to this market for now.
Amazon reports tomorrow after the close, consensus estimates are is calling for revenue $42.25 billion and a loss of $0.01. Revenue is the number that truely counts, in this case. The chart looks decent, and seems to have found support. It is a much-improved picture than one we were looking at Monday.
That’s all for today.
Free Articles From Mike:
We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]
Michael Kramer and the clients of Mott Capital own shares of CELG
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.